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ABBREVIATION
AGT – Angiotensinogen
AGTR1 – Angiotensin 11 receptor type 1
AGTR2 –  Angiotensin 11 receptor 2
CHD – Coronary Heart Disease
VLDL – Very Low Density Lipoprotein
LDL – Low Density Lipoprotein
HDL – High Density Lipoprotein
ICAM1 –  Intercellular Cell Adhesion Molecule 1
VCAM1 – Vascular Cell Adhesion Molecule 1
PeCAM1 – Pericellular Cell Adhesion Molecule1
IL1 – Interleukin 1
TNF-α – Tumour Necrosis Factor-α
PDGF – Platelet Derived Growth Factor
FGF – Fibroblast Growth Factor
RAAS – Renin Angiotensin Aldosterone System
ROS – Reactive Oxygen Species
eNOS – Endothelial Nitric Oxide Synthase
DDAH – Dimethyl Arginine Dimethyl Amino Hydrolase
ADMA – Asymmetric Dimethyl Arginine
DAG – DiAcyl Glycerol
PAI1 – Plasminogen Activator Inhibitor – 1
LVH – Left ventricular hypertrophy
DM – Diabetes Mellitus
HYT – Hypertension
SMK – Smoking
ALC – Alcoholism
WT – Weight
HT – Height
BMI – Body Mass Index
CHOL – Cholesterol
TGL – Triglyceride
EDTA – Ethylene Diamine Tetra Acetic Acid
DNA – Deoxyribonucleic acid
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INTRODUCTION
Atherosclerosis  is  the  biggest  killer  of  21st century  Mechanisms 
contributing  to  atherogenesis  are  multiple  and complex.  Multiple  theories 
including  the  role  of  dyslipedemia,  hypercoagulability,  oxidative  stress, 
inflammation,  endothelial  dysfunction3,4 have  been  put  forth  .Endothelial 
dysfunction is found to play a key role in the initiation of atherosclerosis 
.Endothelial  dysfunction  is  characterized  by  decreased  production  of 
vasodilatory  Nitric  oxide,  prostaglandins  and  increased  production 
vasoconstrictory  angiotensin  2  and  endothelin1.  Increased  production  of 
angiotensin 2 also activates free radical injury to endothelium and decreases 
the availability of NO. This contributes to increased permeability of LDL and 
its  subsequent  oxidation  in  the  subendothelial  space  to  oxidized  LDL, 
inflammation and migration of monocytes, macrophages and smooth muscle 
cells and formation of atherosclerotic lesions .Recently it has been suggested 
that  atherosclerosis  continues  to  have  chronic  inflammation  at  every step 
from the  initiation  to  progression  and  that  all  risk  factors  contribute  by 
enhancing the underlying inflammatory process. Despite changes in lifestyle 
and the use of new pharmacologic approaches to lower plasma cholesterol5,6 
cardiovascular diseases continues to be the principal cause of death7, 8. This 
led the pathway to the identification of genetic factors that determine the 
susceptibility  to  disease  .Coronary  artery  disease  (CAD)  is  a  polygenic 
disease  whose  phenotypic  manifestation  depends  on  the  interaction  of  a 
number of environmental factors. . The genes encoding components of the 
renin-angiotensin  system (RAS)  present  attractive  candidates  for 
cardiovascular disease research. The RAS is present in circulating and tissue-
based  forms and  is  involved  in  sodium  homeostasis,  cardiovascular 
remodelling, and  maintenance  of  vascular  tone.  Angiotensin  I–converting 
enzyme (ACE) is  a  key component  within the RAS, where it  hydrolyzes 
angiotensin I to generate angiotensin II (vasoconstrictor) and the kallikrein-
kinin system, where it inactivates bradykinin (vasodilator). The observation 
that ACE inhibitors reduce atherosclerosis in cholesterol-fed rabbits supports 
the  potential  role  for  ACE or  its  substrates  in  the  development  of 
atherosclerosis.ACE  could  affect  smooth  muscle  cell  and  fibroblast 
migration  and  proliferation,  low-density  lipoprotein  (LDL)  oxidation  and 
endothelial cell function; these are all important factors in atherosclerosis. A 
polymorphic variant of the ACE gene correlates with higher circulating ACE 
levels  and  carries  an  increased  risk  of  myocardial  infarction,  and 
cardiomyopathies. In this study, we sought to determine the distribution of 
ACE  genotypes  and  the  frequency  of  allele  D  in  patients  undergoing 
coronary angiography at our institution. 
REVIEW OF LITERATURE
Coronary heart disease has been defined as impairment of function of 
heart due to inadequate blood supply to the heart compared to its needs 
caused by atherosclerosis. It, being a multifactorial disease has a complex 
etiology.  Many  genetic  and  environmental  factors  act  in  combination  to 
determine an individual’s risk of developing coronary heart disease1. A large 
number of studies such as the Framingham heart study2, The Lipid research 
clinic’s coronary primary prevention trial, the Helsinki Heart study, have been 
conducted to examine the role of risk factors for coronary artery disease. 
The risk factors identified by these epidemiological studies include a group 
of fixed risk factors like positive family history, age, male gender, and a group 
of modifiable risk factors like blood lipid profile abnormalities, hypertension, 
physical inactivity, obesity, cigarette smoking, alcoholism, diabetes mellitus, 
hyperhomocysteinemia2.  Though  overwhelming  evidence  particularly  that 
given by response to “Response to retention hypothesis” indicates that the 
whole sequence of events is found to be initiated by the retention of modified 
Low  Density  Lipoprotein3,4,it  was  identified  later  that  despite  changes  in 
lifestyle  and the  use of  new pharmacologic  approaches to  lower  plasma 
cholesterol5,6 cardiovascular  disease  continues  to  be  principal  cause  of 
death7,8 . 
ATHEROSCLEROSIS
Atherosclerosis is a  disease affecting  arterial blood vessels.  It  is  a 
chronic inflammatory response in the walls of arteries, in large part due to 
the  accumulation  of  macrophages, white  blood  cells promoted  by  low 
density (especially small particle)  lipoproteins without adequate removal of 
fats  and  cholesterol  from  the  macrophages  by  functional  high  density 
lipoproteins (HDL). It is commonly referred to as a "hardening" or "furring" of 
the  arteries.  It  is  caused by the  formation  of  multiple  plaques within  the 
arteries. 
The lesions of atherosclerosis occur principally within the innermost 
layer of the artery wall, the intima .They include9 – 11,
• Fatty streak
• Fibrous plaque
• Complicated lesions
o Plaque disruption
o Atherothrombosis
FATTY STREAK
The  process  of  atherogenesis  begins  in  childhood  with  the 
development of lipid rich lesions called fatty streaks. They are also found to 
contain macrophages, T lymphocytes, smooth muscle cells – each of these 
cells are found to contain deposits of cholesterol and cholesterol oleate. The 
lesions are yellowish and sessile in appearance and they cause little or no 
obstruction  of  the  affected  artery  and  no  clinical  sequelae.  Observations 
suggest that lipid deposition does not inevitably lead to the advanced lesions 
of atherosclerosis but a number of factors are associated with the progression 
of  the  lesions  and  with  the  development  of  more  complex  form  of 
atherosclerosis, the fibrous plaque.
FIBROUS PLAQUE
 The fibrous plaques are derived from fatty streaks that continue the process 
of cell proliferation, lipid accumulation, and connective tissue formation and 
that  the  deep core  of  lipid  and cell  debris  results  from inadequate  blood 
supply, inflammation, and cell necrosis. There is a lesion that is accepted as a 
forerunner of the fibrous plaque – this is known as fibromusculoelastic or 
intermediate  lesion  of  the  intima,  which  consists  of  proliferated  smooth 
muscle cells surrounded by connective tissue and contains little or no lipid. A 
fully  blown  fibrous  plaque  consists  of  numerous  smooth  muscle  cells 
surrounded  by  a  dense  connective  tissue  matrix  often  intermixed  with 
numerous  macrophages.  This  cap  covers  a  deeper  layer  of  macrophages 
filled  with  lipid  that  are  often  intermixed  with  variable  number  of  T 
lymphocytes.
ADVANCED   LESIONS   –   PLAQUE   DISRUPTION   AND 
ATHEROTHROMBOSIS
 The typical advanced, complicated lesion contains a large necrotic core with 
a  fibrous  core,  loaded  with  macrophages.  The  macrophages  can  form 
numerous  proteolytic  enzymes,  including  metalloproteinases  –  these 
enzymes cause the removal of fibrous cap – thus plaque disruption is found 
to  happen  at  the  shoulder  of  the  lesion  where  the  cap  is  thin  and  the 
concentration of macrophages is the greatest. The plaque disruption allow the 
lesion  to  get  involved  in  thrombotic  episodes  that  can  lead  to  occlusive 
disease12Thus, atherosclerosis causes two main problems. 
1. First,  the  atheromatous  plaques,  though  long  compensated  for  by  artery 
enlargement, eventually lead to plaque ruptures and stenosis (narrowing) of 
the artery and, therefore, an insufficient blood supply to the organ it feeds. 
2. Second, if the compensating artery enlargement process is excessive, then a 
net aneurysm results.
These complications are chronic, slowly progressive and cumulative. Most 
commonly,  soft  plaque  suddenly  ruptures,  causing  the  formation  of  a 
thrombus that will rapidly slow or stop blood flow, leading to death of the 
tissues fed by the artery in approximately 5 minutes. This catastrophic event 
is called an infarction. 
The clinical  scenario  of  this  catastrophic  event  depends  on which 
artery is affected by this event. 
1. One of the most common recognized scenarios is  thrombosis of a 
coronary  artery,  causing  myocardial  infarction (a  heart  attack).  This 
condition is called as Coronary artery disease.
2. Second most  common is  that  caused due to  thrombosis  of carotid 
artery branches and inadequate blood supply to brain – which presents itself 
as stroke or transient ischemic attack. 
3. Another common scenario in very advanced disease is  claudication 
from insufficient blood supply to the legs, typically due to a combination of 
both stenosis and aneurysmal segments narrowed with clots. This is called as 
peripheral artery disease.
4. Since  atherosclerosis  is  a  body-wide  process,  similar  events  also 
occur in the arteries of the intestines, kidneys, legs, etc.
HYPOTHESIS OF ATHEROGENESIS
 Atherosclerosis has been recognized in humans for thousands of years. Long 
has discussed the development of clinicopathologic correlations that evolved 
during  the  era  when  autopsy examination  permitted  the  formulation  of  a 
hypothesis  relating  the  degree  of  atherosclerosis  to  the  incidence  of 
myocardial  infarction  and stroke13.  Virchow proposed the  idea  that  some 
form of injury to the arterial wall associated with the inflammatory response 
resulted  in  the  degenerative  lesion  of  atherosclerosis14.  This  idea  was 
subsequently  modified  by  Antischkow15 and  further  included  the  role  of 
platelets  and thrombogenesis  in  atherosclerosis  as  expanded by Duguid16. 
John French noted that the structural integrity of the endothelial lining17 of 
the artery represented a key element in the maintenance of normal arterial 
function and that alteration in endothelial integrity might precede a sequence 
of  events  that  would  lead  to  the  various  forms  of  the  lesions  of 
atherosclerosis.(FIG ;1)
RESPONSE TO INJURY HYPOTHESIS
This  hypothesis  states  that  the  endothelium  helps  to  regulate  the 
homeostasis  of  the  cardiovascular  system.  .The  endothelium  forms  the 
interface between tissues and blood compartment and helps to regulate the 
entry of  molecules  and cells  in  to  the tissues in  a  selective manner  .The 
ability of endothelial cells to serve as a permselective barrier fails in many 
vascular  disorders  including  atherosclerosis.  The  intact  endothelium  is 
capable of releasing antithrombotic and fibrinolytic factors in addition to the 
potent vasodilator nitric oxide (NO). In normal blood vessels, NO and acetyl 
choline induce vasodilatation, but with endothelial damage,disruption of the 
cell state negates normal function and the actions of potent vasodilators, the 
damaged  endothelium  causes  abnormal  responses  from  acetylcholine 
increasing the production of vasoconstricting agents such as thromboxane A2 
and  prostaglandins,in  addition  to  eliciting  the  development  of  abnormal 
intracellular ca2+ and endothelin derived vasoconstricting factor 
The endothelial dysfunction is associated with overexpression of E, 
L, P selectin that appear to play a role in inducing rolling and attachment of 
monocytes and T lymphocytes to endothelium. This rolling is facilitated by 
the upregulation of ICAM 1 and VCAM 1 also. Another molecule formed by 
endothelium, PeCAM 1 has  been shown to  participate  in  interendothelial 
migration by the adherent leukocyte into the subendothelial space or intima 
of the artery. Thus, the earliest phase of the chronic, inflammatory response 
that  has  become  recognized  to  be  the  hallmark  of  atherogenesis  is 
represented by leukocyte adhesion due to the formation of these attachment 
and  adherence  molecules  on  the  surfaces  of  the  endothelium  and  the 
leukocytes18-–20.
A  second  event  accompanying  endothelial  dysfunction  is 
transmigration  of  lipoproteins  particularly  of  small  LDL  particles,  this 
transmigration  places  LDL in  the  subendothelial  space  which  is  virtually 
devoid of any antioxidant properties of the circulation, hence it gets oxidised. 
Oxidised LDL can act as one of the chemotactic reagents and can also induce 
the  endothelial  cells  and  the  underlying  smooth  muscle  cells  to  form  a 
second  chemotactic  factor,  monocyte  Chemoattractant  protein  1  (MCP-1) 
and a colony stimulating factor (M-CSF). In this scenario, the monocyte gets 
activated to macrophages, which express SR-B1 causing unregulated uptake 
of  LDL  particles,  forming  foam  cells.  Such  a  lesion  with  foam  cells, 
activated inflammatory cells is called as fatty streak. 
Oxidised  LDL,  foam  cells,  the  activated  macrophages,  T-cells 
produce  various  cytokines  IL-1,  TNF-α..  Under  the  influence  of  these 
cytokines,  endothelium,  macrophages  and  Tcells  produce  PDGF,  FGF21. 
PDGF  stimulates  smooth  muscle  cell  migration  and  proliferation.  FGF 
stimulate  the  vascular  smooth  muscle  cell  to  produce  collagen  and  the 
various components of extracellular matrix together they form the fibrous 
cap. TNF- α induces apoptosis of foam cells causing exocytosis of its lipid 
content, which forms the lipid core. Such a lesion with lipid core, surrounded 
by activated T-cells, macrophages, platelets (occasionally), lined by a fibrous 
cap is called as a stable atherosclerotic plaque. Thus oxidised LDL is not 
only toxic to the endothelium and the surrounding cells in the intima but also 
chemotactic for monocytes and can activate monocyte derived macrophages 
to  produce  growth  factors  and  cytokines.  Hence  it  may be  the  principal 
culprit in advancing the lesions of atherosclerosis.
If  the  injury  to  the  endothelium were  a  self-limited  event  and  if 
endothelial function were restored, the proliferative lesions might be capable 
of regressing. If this were the case, the lesions would be reversible and, if 
they had not reached a critical size, would be clinically silent. On the other 
hand, if the injury at focal sites in the artery wall is either of long standing or 
chronically repeated over period of many years, the lesion could continue to 
progress,  becoming  increasingly  complex  in  terms  of  their  composition. 
Because, the atherosclerotic plaque does not only have smooth muscle cells 
but  also macrophages,  which are capable of producing metalloproteinases 
and TNFα, both of which cause necrosis and digestion of the fibrous cap, this 
loss of fibrous cap is responsible for the complications of atherosclerosis, 
namely  plaque  rupture.  This  plaque  rupture  exposes  the  subendothelial 
extracellular matrix to the factors of coagulation in the circulation initiating 
the  intrinsic  pathway  of  coagulation  –  this  is  responsible  for 
atherothrombosis. 
FACTORS INFLUENCING ATHEROGENESIS
UNMODIFIABLE RISK FACTORS
1. Age
2. Male sex
3. Family History
MODIFIABLE RISK FACTORS
1. Cigarette smoking
2. Alcoholism
3. Insulin resistance & hyperglycemia
4. Hypertension
5. Obesity
6. Oxidative stress
7. Abnormal lipid profile
a. High total and LDL cholesterol
b. Low HDL cholesterol
8. High triglycerides
9. Lipoprotein(a)
10. Physical inactivity
Age
Age is a dominant influence .Death rates from ischemic heart disease 
rise  with  each  decade  even  into  advanced  age,  atherosclerosis  is  not 
clinically  evident  until  middle  age  or  later,  when  the  arterial  lesions 
precipitate  organ  injury.  Between  ages  of  45  and  60  the  incidence  of 
myocardial  infarction  increases  fivefold.  Age  related  changes  in 
cardiovascular system include diastolic dysfunction, degenerative changes in 
the conduction system, reduced responses to catecholamine and sympathetic 
stimuli. The oxidative stress associated with ageing and the co morbidity i.e., 
the appearance of the other risk factors are often cited as a reason for the 
high rates of CAD associated mortality and complications.
Male sex
 The  relationship  of  gender  to  the  development  and  prognosis  of 
atherosclerotic  coronary  heart  disease  is  complicated22.  Decades  of 
observational studies have verified excess coronary risk in men compared 
with premenopausal women. At least part of the apparent protection against 
CAD in women derives relatively from their relatively higher HDL values 
compared  to  men  .After  menopause,  HDL  values  fall  in  concert  with 
increased  coronary risk.  Women tend to  develop  atherosclerotic  coronary 
heart disease approximately 10 years later than men. 
 This gender dependent differential risk is attributed to the protective function 
exerted  by  estrogens.  Recently,  a  study  of  estrogens  and  their  effect  on 
smooth muscle cells  and the other elements of atherogenesis  showed that 
estrogens have an antiproliferative effect on smooth muscle cells and can be 
protective to the endothelium in relation to stimulation by growth factors, 
cytokines  and  other  agents.  Oestrogen  is  not  only  anti  proliferative  for 
smooth  muscle  but  also  has  been  shown  to  be  capable  of  modulating 
acetylcholine mediated dilation of atherosclerotic coronary arteries23. 
Family history of Early- Onset CHD
 Over 35 case-control and prospective studies have consistently identified an 
association between CHD and a history of first degree relatives with early 
onset CHD73. This risk generally persists even after adjustment for other risk 
factors. The family history most predictive of coronary disease is that of a 
first degree relative developing CHD at an early age. Although CHD in a 
male relative with onset at age 55 or less or a female relative with onset at 
age 65 or less is defined as a positive family history, the larger the number of 
relatives with early onset of CHD or the younger the age of CHD onset in the 
relative, the stronger the predictive value 74,75.
Socioeconomic status
 A consistent relationship has been established between lower socioeconomic 
status and atherosclerosis. There has been the perception that conventional 
risk factors cluster in lower socioeconomic groups and that this phenomenon 
can  explain  the  increased  incidence  of  atherosclerotic  coronary  heart 
disease24. However only 50% of atherosclerotic coronary heart disease can be 
explained by known risk  factors.  The socioeconomic  status  proved to  be 
independent predictors in patients with established atherosclerotic coronary 
heart  disease25.  Although  no  simple  relationship  between  socioeconomic 
status, risk for cardiovascular disease and long term outcome for manifest 
atherosclerotic  coronary  heart  disease  can  be  devised,  the  evident  is 
consistent and persuasive that lower socioeconomic status is an independent 
and significant determinant of long-term outcome.
Hypertension
Several  major  prospective  epidemiological  studies  have  found  that  both 
systolic  and  diastolic  hypertension  have  a  strong,  positive  and  graded 
relationship to CHD without evidence level of a threshold risk level of blood 
pressure26-27.  The risk imposed by hypertension is heightened substantially 
when  other  risk  factors  are  present.  Hypertension  clusters  with  insulin 
resistance,  hyperinsulinemia,  glucose  intolerance,  dyslipidemia,  left 
ventricular hypertrophy and obesity and occurs in isolation in  fewer than 
20% of individuals28
The  potential  mechanisms  by  which  hypertension  may  cause  impaired 
endothelial  function  include  increased  endothelial  permeability  to 
lipoproteins, increased adherence of leukocytes, increased oxidative stress, 
and  hemodynamic  stress  that  may trigger  acute  plaque  rupture,  all  these 
mediated by activation of NF-kB pathway and inactivation of eNOS enzyme. 
Hyperglycemia
 Hyperglycemia is an independent risk factor for CHD, increasing the risk by 
two to three times for men and three to five times for women 29. CHD is the 
leading cause of death in diabetic patients and approximately 25% of MI 
survivals  have  diabetes  30. The  CHD  risk  for  a  premenopausal  diabetic 
woman is similar to the risk of a nondiabetic man, hence diabetes abolishes 
the protective effect of being a premenopausal female  31. Diabetic women 
have  twice  the  risk  of  recurrent  MI  compared with  diabetic  men  32.  The 
greater risk of CHD in diabetic women compared to diabetic men may be 
explained in part by the greater adverse effect of diabetes on lipoproteins in 
women 33. 
Potential  mechanisms  by which  hyperglycemia  may cause  atherosclerosis 
include  impaired  endothelial  function,  glycation  of  LDL,  enhanced 
lipoprotein  oxidation,  increased fibrinogen,  increased platelet  aggregation, 
increased PAI-1, impaired fibrinolysis, increased small LDL. All these are 
attributed to the increased flux of glucose into glycolysis (glucose uptake and 
hexokinase activity in endothelium is insulin independent), as a result there 
is  an  increased  NADH/NAD  ratio,  causing  increased  flux  of  electrons 
through electron transport chain, producing superoxide radicals. This cause 
DNA  damage  and  the  resultant  ADP  ribosylation  of  proteins  inhibit 
glyceraldehyde  3  phosphate  dehydrogenase  of  glycolysis,  causing 
accumulation  of  glyceraldehyde  3  phosphate  and its  precursor  fructose  6 
phosphate. The former causes activation of protein kinase C pathway through 
DAG  –  protein  kinase  C  pathway  stimulates  the  production  of  various 
cytokines  and  thereby  stimulates  inflammation.  Fructose  6  phosphate 
stimulates hexosamine pathway, thereby stimulate N- glycosylation of many 
proteins like eNOS and inhibition of them, this causes NOS uncoupling and 
the resultant oxidative stress further aggravates the condition. Furthermore, 
there is increased formation of advanced glycation end product, which on 
binding to receptor for advanced glycation end products is found to stimulate 
NFkB pathway, causing all the features of atherosclerosis.
Insulin resistance and hyperinsulinemia
 Resistance to insulin and compensatory hyperinsulinemia are the common 
metabolic basis of cluster of coronary risk factors, particularly hypertension, 
diabetes, hypertriglyceridemia, low HDL, predominance of small LDL, and 
an  increased  plasminogen  activator  inhibitor  concentration  35,  36. 
Hyperinsulinemia  may  rise  blood  pressure  through  sympathetic  nerve 
stimulation and/or  renal  sodium retention.  Insulin sensitivity is  associated 
with endothelial nitric oxide production in healthy persons providing a clue 
as  to  how  insulin  resistance  may  promote  CHD  directly37.  Furthermore, 
hyperinsulinemia has been found in a prospective study to be an independent 
risk  factor  for  CHD in  nondiabetic  men after  adjusting  for  body weight, 
blood pressure and dyslipidemia38.
Physical inactivity
 Physical  inactivity roughly doubles  the risk of  CHD. Moderate  intensity 
exercise reduces  coronary atherosclerosis  and widens coronary arteries  in 
monkeys fed on atherogenic diet compared with monkeys fed the same diet 
but  forced  to  be  sedentary39.  Physical  activity  slows  progression  of 
angiographically  defined  coronary  atherosclerosis  in  human40.  Over  50 
observational  studies,  primarily  of  men,  have  established  that  physical 
fitness,  on  the  job of  physical  activity,  and leisure  time  physical  activity 
reduce the risk of CHD41. Higher levels of physical fitness and leisure time 
physical activity are associated with lower rates of mortality, independent of 
other  risk  factors41.  The  risk  of  MI  and  sudden  cardiac  death  is  greatest 
during exercise,  leading some to question the benefits  of exercise  42.  The 
overall risk of MI and sudden cardiac death, is however low among those 
who exercise regularly. The greatest reduction in risk is between sedentary 
individuals and those who do regular moderate intensity activity. 
In  addition  to  decreasing  myocardial  oxygen  demand  and  increasing 
myocardial efficiency and electrical stability, other potential mechanisms by 
which  physical  activity  may  reduce  CHD  risk  include  increasing  HDL, 
reducing  blood  pressure,  reducing  obesity,  improving  insulin  sensitivity, 
decreasing platelet aggregation and increasing fibrinolysis41 .
Obesity
Obesity promotes insulin resistance, hyperinsulinemia, hypertriglyceridemia, 
low HDL cholesterol, and LVH 43, 44. Many observational studies have found 
that  obesity  strongly  and  positively  correlates  with  the  risk  of  CHD  in 
univariate analysis. In multivariate analysis, when controlling statistically for 
risk factors such as hypertension, diabetes, and dyslipidemia, obesity is not 
found to be an independent risk factor. Rather it reflects that much of the 
adverse consequences of obesity are mediated through resultant metabolic 
risk factors acting as pathological links in the causal pathway. Nevertheless, 
some large prospective observational studies of long duration indicate that 
obesity  is  an  independent  risk  factor  for  coronary  and  cardiovascular 
mortality  in  men  and  women  45-47.  In  general,  the  greater  the  degree  of 
overweight, the higher the risk of coronary mortality. The central distribution 
of body fat  predicts  CHD in men independently of body-mass index and 
other  major  risk  factors  48.  Weight  loss  improves  insulin  sensitivity  and 
glucose  disposal;  reduces  blood  pressure,  triglycerides  and  LVH;  and 
increases HDL cholesterol 43-44.
Oxidative stress
 Excessive production of reactive oxygen species has been implicated to play 
an  important  role  in  a  number  of  cardiovascular  pathologies,  including 
hypertension,  atherosclerosis,  myocardial  infarction,  ischemia/reperfusion 
injury. ROS are generated in vascular cells by NADPH oxidases, uncoupled 
eNOS,  and  other  enzymatic  sources  or  as  a  product  of  mitochondrial 
respiration49. If this production goes unbalanced, it leads to exacerbation of 
pathophysiological  processes.  Superoxide  radicals  are  found  to  cause 
oxidative  modification  of  LDL.  OxLDL,  by activating  NFkB pathway of 
inflammation is found to mediate the increased production of IL-1, increased 
expression  of  ICAM, both  of  which  mediate  the  rolling  of  inflammatory 
cells. Furthermore there is increased production of PDGF and FGF, both of 
which cause smooth muscle cell proliferation and migration. This cycle is 
reinforced by the decreased production of NO, because the superoxide cause 
nitrosylation  of  eNOS  and  thereby  it  inhibits  the  enzyme  activity.  The 
decreased NO causes increased vascular reactivity and the resultant shear 
stress  will  further  stimulate  NFkB  pathway.  Thus  oxidised  LDL  is 
hypothesized  to  play  a  major  role  in  the  initiation  and  progression  of 
atherosclerosis 50,51,52,53. 
Cigarette smoking
Strong  dose  relationships  between  cigarette  smoking  and  coronary  heart 
disease have been observed in both sexes. Cigarette smoking increases risk 
two  to  threefold  and  interact  with  other  risk  factors  to  multiply  risk. 
Pathophysiological studies have identified panoply of mechanisms through 
which cigarette smoking may cause CHD. Smokers have increased levels of 
oxidation products, including oxidised LDL. Cigarette smoking also lowers 
the cardioprotective levels of high density lipoproteins (HDL). These effects, 
along  with  direct  effects  of  carbon  monoxide  and  nicotine,  produce 
endothelial  damage.  Possibly,  through  these  mechanisms,  smokers  have 
increased vascular reactivity54. Cigarette smoking is also related to increased 
levels of fibrinogen55 and increased platelet  aggregability56.  Thus cigarette 
smoking paves way for atherosclerosis by inducing oxidative stress and by 
altering coagulability.
DYSLIPIDEMIA
Total cholesterol and LDL cholesterol
Numerous prospective studies have identified a continuous, graded and direct 
relationship between serum cholesterol and CHD incidence  57. The level of 
total and LDL cholesterol interacts with other risk factors to multiply risk 58. 
Elevated LDL cholesterol levels have been related to recurrent events and 
CHD death in patients with established CHD  59. Elevated LDL cholesterol 
levels appear to be involved with all stages of atherogenesis – endothelial 
dysfunction,  plaque  formation  and  growth,  and  plaque  instability  and 
disruption.  Elevated cholesterol  levels  in  the plasma lead to an increased 
retention  of  LDL particles  in  the  arterial  wall,  their  oxidation  and  the 
secretion of various inflammatory mediators and chemoattractants 60. LDL is 
also  a  potent  mitogen  for  smooth  muscle  cells;  progressive  growth  of 
atherosclerotic plaques can be halted by lowering of LDL cholesterol levels. 
Atherosclerotic  plaques  with  a  large  lipid  core  and numerous  lipid  filled 
macrophages  are  prone  to  rupture  61.  Thus  the  epidemiological  evidence 
strongly supports LDL-cholesterol’s role in atherosclerosis.
Furthermore, small dense LDL are felt to be more atherogenic  62. Possible 
explanation for this is that when a person has more of small LDL particles, 
for a given cholesterol content, the number of LDL particles will be more, 
and an LDL receptor can accept only one LDL particle at a time and hence 
the rate of metabolism of LDL is decreased, causing accumulation of LDL in 
the plasma. The second reason for the same is the endothelium will be more 
permeable to small LDL particle when compared to a normal LDL.
Triglycerides
The relationship between triglycerides and CHD has been less clear. In men, 
univariate  analysis  have  consistently  demonstrated  a  direct  dose-response 
relationship. This relationship usually disappears after adjustment for other 
risk  factors  such  as  HDL  cholesterol,  obesity,  and  diabetes  63. 
Hypertriglyceridemia  however  has  been  found  to  be  an  independent  risk 
factor in women 64. Several mechanisms have been proposed to explain the 
triglyceride- CHD association. First, some patients with hypertriglyceridemia 
have  a  predominance  of  small,  dense  LDL  particles.  Second,  fasting 
hypertriglyceridemia  may  be  a  marker  of  exaggerated  postprandial 
hyperlipidemia, which may promote the uptake of atherogenic triglyceride 
rich lipoprotein remnants by endothelial cells65. Finally, serum triglyceride 
levels  are  strongly  related  to  fibrinogen  and  factor  VII  in  numerous 
epidemiological  studies66.  Therefore,  a  number of  mechanisms,  direct  and 
indirect link serum triglycerides and CHD.
Low HDL cholesterol
Numerous  prospective  epidemiological  studies  have  demonstrated  a 
continuous,  inverse  relationship  between  HDL cholesterol  levels  and  the 
incidence of CHD 67. The total cholesterol to HDL cholesterol ratio is a better 
predictor of CHD than the HDL cholesterol level alone  67. Two important 
mechanisms  by  which  HDL is  thought  to  play  a  protective  role  against 
atherosclerosis  are  reverse  cholesterol  transport  and  inhibition  of  LDL 
oxidation. 
ANGIOTENSIN-CONVERTING ENZYME (ACE)
Angiotensin-converting  enzyme  (ACE)  is  a  zinc  metallopeptidase 
widely  distributed  on  the  surface  of  endothelial  and  epithelial  cells. 
Angiotensinogen is converted to angiotensin I by stimulation of renin. ACE 
then converts angiotensin I to angiotensin II, the main active product of the 
renin–angiotensin–aldosterone  system  (RAAS).  The  human  ACE  gene  is 
located on chromosome 17q23, and includes 26 exons. The coding sequence 
codes for a 1306 amino acid protein, including a single peptide. The gene 
product, ACE, is composed of 2 homologous domains with 2 active sites. 
The ACE gene product plays an important role in cardiovascular homeostasis 
as  ACE converts  angiotensin  I  to  angiotensin  II,  and  is  involved  in  the 
degradation of bradykinin. Bradykinin acts as a potent stimulator of nitric 
oxide (NO) release. NO plays a crucial role in protecting the endothelium 
from injury. Furthermore, it has been reported that hypertensive effects are 
mediated  in  a  bradykinin-dependent  manner.  The  ACE  gene  contains  a 
polymorphism in the form of either insertion (I) or deletion (D) of a 287 base 
pair Alu repetitive sequence in intron 16. This polymorphism is shown to be 
associated  with  the  interpersonal  variability  of  ACE levels  in  circulating 
blood.  The  deletion  allele  at  this  gene  site  is  associated  with  increased 
plasma ACE activity. Conflicting results have been reported regarding the 
association of ACE polymorphism with coronary artery disease (CAD).To 
date, there have been no data from South India to determine any association 
of  ACE  polymorphism with  CAD  or  myocardial  infarction  (MI).  In  the 
present  study,  an attempt has been made to address the question whether 
ACE polymorphism has any positive association with CAD patients from the 
South Indian state of Chennai. Available epidemiologic studies on Indians 
show a rise in the prevalence of CAD in urban Indians. Conventional risk 
factors  for  CAD do not  completely account  for  the  observed increase  in 
premature CAD in people from the Indian subcontinent or in Asian Indians 
who have immigrated to the USA and Europe. As the incidence of CAD is 
increasing in India, especially in the younger population, it is important to 
identify the risk factors for CAD. 
STRUCTURE OF ACE
There are two forms of ACE in humans, encoded by a single gene 
located on chromosome 17 at q23; it  is 21 kb in length and contains 26 
exons and 25 introns. The longer form, known as somatic ACE (sACE), is 
transcribed from exons 1-12 and 14-26, whereas the shorter form, known as 
germinal  or testicular ACE (gACE),  is transcribed from exons 13-26. The 
promoter for s ACE is in the 5' flanking region of the first exon, whereas that 
for  g  ACE  is  located  within  intron  12  132.  Somatic  ACE  consists  of  an 
intracellular domain, a transmembrane domain and two similar extracellular 
domains, the amino or N domain and the carboxy or C domain. The structure 
of the ACE gene is the result of gene duplication; the N and C domains are  
similar  in  sequence,  and  the  homologous  exons  encoding  the  N  and  C 
domains (exons 4-11 and 17-24, respectively) are very similar in size and 
have similar codon phases at exon-intron boundaries. Each of the domains 
contains a catalytically active site characterized by a consensus zinc-binding 
motif (HEXXH in the single-letter amino-acid code, where X is any amino 
acid) and a glutamine nearer the carboxyl terminus that also binds zinc; ACE 
and its homologs therefore make up the M2 gluzincin family 133.
 The X-ray structure of testicular ACE, and its complex with the widely used 
ACE  inhibitor  lisinopril,  at  2.0  Å  resolution  has  been  elucidated.  This 
structure was determined using the anomalous scattering of the bound Zn 
atom  at  beam  line  BM14 of  the  ESRF.The  three-dimensional  structure 
reveales  that  ACE  is  composed  of  a-helices  for  the  most  part,  and 
incorporates a zinc ion and two chloride ions (Figure 33). In fact it bears 
little  resemblance  to  carboxypeptidase  A except  in  the  active  site  zinc-
binding motif. Instead, it resembles rat neurolysin and Pyrococcus furiosus 
carboxypeptidase, despite sharing little amino-acid sequence similarity with 
these two proteins. This similarity extends to the active site, which consists 
of a deep, narrow channel that divides the molecule into two subdomains. On 
top of the molecule is an amino-terminal 'lid', which seems to allow only 
small peptide substrates (2530 amino acids) access to the active site cleft this 
accounts for the inability of ACE to hydrolyse large, folded substrates.
The Genes of the RAS: 
The  genes  encoding  components  of  the  renin-angiotensin  system 
(RAS)  present  attractive  candidates  for  cardiovascular  disease.  The  RAS 
gene  system  comprises  the  renin,  angiotensinogen  (AGT),  angiotensin I-
converting  enzyme  (ACE),  and  angiotensin  II  receptor  types 1  and  2 
(AGTR1, AGTR2) genes. The renin gene maps to chromosome 1q32, spans 
approximately 12 kb,  and  comprises  10  exons  and  nine  introns.68, 69 The 
angiotensinogen gene maps to chromosome 1q42–43, spans approximately 
13 kb, and comprises five exons and four introns70, 71 ; exons 1 and 5 encode 
for the 5' and 3' untranslated regions of mRNA, respectively.  The ACE gene 
maps to chromosome 17q23, spans 21 kb, and comprises 26 exons and 25 
introns.72, 73 The two major species of ACE mRNA are a 4.3-kb endothelial-
type mRNA (transcription encompassing exons 1 to 26, excluding exon 13) 
and a 3-kb testicular type ACE mRNA (transcription encompassing exons 13 
to 26). Exon 26 encodes for the functionally important membrane-anchoring 
domain of the ACE protein. The endothelial type of ACE mRNA is found not 
only  in  endothelial  cells,  but  also  in  epithelial  cells.  The  angiotensin  II 
receptor type 1 gene maps to chromosome 3 and the angiotensin II receptor 
type  2  gene  maps  to  
chromosome X.74,75
Circulating RAS Components
RAS functions as an endocrine system. The renin gene is expressed 
primarily in  the  juxtaglomerular  cells  of  the  kidney,  where  renin  is 
synthesized, stored, and released into the circulation. Prorenin is cleaved  to 
form renin, which is stored in tissue granules until it is released  in response 
to specific secretagogues. Secretion of renin from the kidneys is controlled 
by  several  factors.  The  macula  densa  are a  specialized  group  of  distal 
convoluted tubular cells that act as chemoreceptors for sodium and chloride 
levels in the distal tubule. Sodium retention increases blood volume, which is 
followed by an increase in blood pressure. This increase in blood pressure 
activates a negative feedback regulation of the juxtaglomerular cells in the 
kidney,  which  sense  renal  perfusion pressure  and  renin  production  are 
inhibited.  Renin  secretion is  autonomically  modulated  via  sympathetic 
innervation of the renal tubules and arterioles. 
Circulating  renin  catalyzes  the  angiotensinogen-to-angiotensin I 
conversion. The angiotensinogen gene is expressed in the liver, the site of 
AGT synthesis and release into the circulation.  The angiotensin I (Ang I) 
generated  by  renin  activity  is  a  vasoinactive  decapeptide.  Conversion  of 
angiotensin  I  to  angiotensin  II  (Ang II)  is  the  key  reaction  in  the  RAS 
pathway,  generating  the  effector of  the  system,  Ang  II,  a  potent 
vasoconstrictor. The reaction is catalyzed by ACE (kininase II; EC 3.4.15.1), 
a  zinc  metallopeptidase member  of  the  Alu  family  that  functions  as  a 
dipeptidyl  carboxypeptidase (DCP1).  The  mechanisms  controlling  the 
circulating ACE levels are less clear than those for renin. The most likely 
genetic control  is  at  the  level  of  transcription  and would  involve  linkage 
disequilibrium with regulatory elements of the ACE gene. Once the protein is 
translated and bound to the cell membrane, release would require cleavage of 
the hydrophobic bonds that anchor the protein to the membrane. ACE cleaves 
the  C-terminal  His-Leu  dipeptide  from  Ang  I,  generating the  vasoactive 
octapeptide Ang II.76Further conversion of Ang II to Ang III is possible by 
cleavage of the aspartic acid from position 1 of the octapeptide; however, the 
generated  Ang III  is  less  potent  as  a  vasoconstrictor,  compared  to  Ang 
II.76Circulating ACE is found in biological fluids, such as plasma, amniotic 
and seminal fluids, and originates from endothelial cells. 
ACE also acts as a protease on bradykinin, cleaving the C-terminal 
Phe-Arg dipeptide,  with  the  net  effect  of  inactivating  this  vasodilator. 
Therefore, ACE enzymatic activity will result in a double effect: activation of 
a  vasoconstrictor/pressor  (Ang  II)  agent  and  inactivation of  a  vasodilator 
agent  (bradykinin).  Ang  II  is  also  an  aldosterone-stimulating peptide. 
Aldosterone promotes depletion of potassium while promoting the retention 
of sodium and water; therefore Ang II exerts a negative feedback on rennin 
production  due  to  volume  expansion and/or  to  a  direct  effect  on 
juxtaglomerular cells. 
Tissue RAS Components
RAS also functions as a paracrine system. Ang II is demonstrated to 
be  produced  in  multiple  target  organs  by  local  RAS  pathways.  All 
components  of  the  RAS,  for  example,  are  present  in  cardiac  tissue77,  78 ; 
transcripts for all RAS components are found in both atrial  and ventricular 
tissue.79, 80 However,  under  normal  conditions the  renin  responsible  for 
local/cardiac Ang I generation appears to derive from circulation, being of 
renal origin. Under pathological conditions, renin can be also produced in the 
heart.81 The key component of the tissue RAS, as in circulating RAS, is ACE. 
At the cellular level, the ACE molecule projects into the extracellular space 
and  is  anchored  to  the  plasma membrane by the  C-terminal hydrophobic 
region that spans the membrane and ends in a short  cytoplasmic tail. Ang II 
generated  by ACE activity  exerts  its effects  by binding to  angiotensin  II 
receptors, type 1 and type 2; AGTR1 is the major mediator of physiological 
effects of Ang II (vasoconstriction, hypertrophy,catecholamine liberation at 
sympathetic  nerve endings).  Both AGTR1 and AGTR2 are  transmembrane 
receptors, comprising seven membrane-spanning domains, and are coupled to 
G-proteins.  Both AGTR1 and  AGTR2 mRNAs are  expressed in  the  heart. 
However,  AGTR1 is  the  principal  receptor  mediating Ang II  cardiac  and 
circulatory effects. Cardiac effects include direct inotropic activity resulting 
in increased myocardial contraction, as well as cell growth and proliferation, 
resulting in  cardiac  remodelling,  hypertrophy,  and  ventricular  dilatation.76 
AGTR2 appears to be the dominant receptor in both atrial  and ventricular 
myocardium, as well as in the adrenal medulla and uterus.76, 82 Functionally, 
AGTR2 is an antagonist of AGTR1, in as much as it has an antiproliferative 
effect.83 
Ang II can also be generated in the tissues, including myocardium,  by 
pathways  other  than  RAS;  non-RAS  pathways  involve  nonspecific 
carboxypeptidases and chymotrypsin-like proteinases. An example of one of 
these is  chymase  (serine-proteinase),  which  catalyzes  an  efficient  Ang II 
generation  at  tissue  levels.  Production  of  Ang  II  by  these  non-RAS 
alternative pathways is not inhibited by therapy with ACE inhibitors. The 
chymase  pathway has  been  demonstrated  in  various  cell  types, including 
myocardium, endothelial cells, and mast cells.84, 85 Chymase levels have been 
found higher in the ventricles than in the atria, and ventricle levels do not 
appear to change significantly in heart failure.85 
The ACE gene polymorphism was first reported by Rigat et al in a 
study that  addressed  the  role  of  the  ACE gene  in  the  genetic control  of 
plasma  ACE  levels.86  Normally,  plasma  ACE  levels show  marked 
interindividual variation but appear to be remarkably stable when measured 
repeatedly in the same subject. The normal ranges for plasma ACE levels and 
the units of measurement depend on the detection method used. Rigat et al 
used  direct  radioimmunoassay measurement  of  the  enzyme  (in  µg/L); 
subsequently, functional assays using spectrophotometric measurements (in 
U/L) havebeen used. Reference ranges for each method must be established 
in the  testing  laboratory.  A  current  and  widely  used  method  is  a 
spectrophotometric method using the synthetic tripeptide substrate  N-[3-(2-
furyl)acryloyl]-L-phenyl-alanylglycylglycine  (FAPGG). The  normal  ranges 
are age-dependent and vary widely in adults (8–52 U/L).A previous study of 
healthy  families  had  shown  intrafamilial  similarities of  ACE  levels, 
suggesting  they  are  controlled  by  a  major  gene.87 The  polymorphism 
discovered  by Rigat  et  al  is  of  the  insertion/deletion type;  the  two ACE 
alleles differ in size because of the insertion of a 287-bp DNA sequence in 
intron 16 of the ACE gene.86  The ACE polymorphism was initially detected 
by restriction fragment length polymorphism (RFLP) analysis and Southern 
hybridization with a human ACE cDNA probe.86 Subsequent studies of ACE 
polymorphism and  disease  associations  used  polymerase  chain  reaction 
(PCR) for genomic DNA amplification. The first PCR-based detection  of the 
I/D ACE polymorphism was reported by Rigat et  al,88 who used a set  of 
primers  flanking  the  insertion  sequence;  the  generated amplicons 
corresponding to the I and D alleles differ in size by the length of insertion 
sequence (ie, 287 bp) and allow discrimination between the three genotypes: 
II, ID, and DD. 
Effect of Genotype on Enzymatic Levels
The ACE DD genotype is associated with increased circulating ACE 
levels, which are generally two times as high as those found for II genotypes; 
ID  heterozygotes  are  associated  with  intermediate ACE  levels.98 This 
relationship of  D allele  dose and enzymatic  levels, originally reported by 
Rigat et al, was repeatedly confirmed by other studies, for both circulating 
and cellular ACE.99,100,101,102However, because the ACE I/D polymorphism is 
intronic,  the  mechanism  of  ACE  overexpression in  subjects  with  DD 
genotype  is  unclear.  It  is  thought  to  be  in  linkage  disequilibrium with  a 
functional mutation in the gene. 140,141
Ang II, superoxide anions, and Inflammation
Reactive oxygen species (ROS), generated by the membrane-bound 
NADPH-oxidase system94 and stimulated by Ang II via its AT1-receptor, seem 
to be a pivotal step for atherosclerosis ; it is possible that this relationship is 
the result of tight linkage to another locus involved in the regulation of ACE 
gene  expression.107  DD genotype  associated  with  increased  ACE activity 
results  in  increased  Ang  l  l  production  and  thereby  it  contributes  to 
atherosclerosis. Griendling et al. first demonstrated that Ang II stimulates the 
generation of ROS in  vascular  cells and macrophages,  which are known 
activators for cytoplasmic signaling cascades such as nuclear factor-kB (NF-
kB), mitogen-activated protein (MAP) kinases, or the Janus tyrosine kinases 
(JAK)/signal  transducers  and  activators  of  transcription  (STAT)  cascade 
90,91.Together,  these mechanisms may enhance oxidative stress within the 
vascular wall and lead to the activation of redox-sensitive genes, such as 
those for proinflammatory cytokines92. These observations suggest that Ang 
II may, via redox-sensitive mechanisms, activate IL-6 synthesis and release. 
Moreover,  recent  observations  indicate  that  proinflammatory  eicosanoids, 
such  as  leukotriene  B4  or  thromboxanes,  are  involved  in  AT1-receptor-
dependent NADPH-oxidase activation. This latter pathway does not only link 
inflammation with the RAS but also links it with prothrombotic mechanisms. 
In  this  regard,  proinflammatory eicosanoids  are  elevated  in  patients  with 
unstable angina and play a critical role based on its vasoconstrictive and 
mitogenic potencies. When blocking the Ang II-induced effects by chronic 
ACE  inhibition,  macrophage  recruitment  into  the  vessel  wall  can  be 
abolished in a rabbit model of atherosclerosis and apoE-deficient mice103,104. 
Moreover,  blockade  of  the  AT1  receptor  by  losartan  prevents  the 
accumulation of oxidative reactants in the atherosclerotic vessel  wall  and 
reduces the quantity of  atherosclerotic  lesion in  an apoE-deficient  animal 
model and monkeys103,104. Thus the interaction between ROS, inflammatory 
cells, and the RAS seemed to be important not only for the development of 
acute coronary syndrome, but also for the progression of atherosclerosis . 
With regard to  the development of  atherosclerotic  lesions,  evidence from 
other  animal  models,  including  rodents  and  primates,  shows  that  ACE 
inhibition  may  reduce  the  extent  of  vascular  lesions103-105.  Additional 
mechanisms by which the RAS via Ang II may enhance the development of 
atherosclerosis involve the activation of thrombosis pathways via PAI-1 95,96,97 
or  the  stimulation  of  pro-inflammatory  cytokines.  Diet  et  al.106  first 
demonstrated  that  Ang  II–forming  protease  ACE is  expressed  in  human 
atherosclerotic  plaques.  The  authors  demonstrated  that  in  early-  and 
intermediate-stage  atherosclerotic  lesions,  ACE  was  predominantly 
expressed  in  lipid-laden  macrophages  (similarly  to  pro-inflammatory 
cytokines) whereas in advanced lesions ACE was predominantly localized 
throughout  the  plaques  microvasculature105.  Potter  et  al.  further 
demonstrated  that  lipid-laden  macrophages  contain  Ang  II  in  a  primate 
model of atherosclerosis. In humans, at least two major enzymes, ACE and 
chymase,  are  involved  in  the  conversion  of  Ang  I  to  Ang  II  and  may 
contribute  to  Ang  II  formation  in  coronary  arteries.  Further  investigations 
demonstrated that in normal and atheromatous coronary artery segments of 
patients  dying  of  noncardiovascular  diseases  that  only  ACE,  but  not 
chymase, was co localized with Ang II in the intima of stable atherosclerotic 
plaques. These findings suggest that ACE is apparently the primary source 
of Ang II in atherosclerotic human coronary arteries. Interestingly, Hoshida et 
al.  demonstrated  that  tissue  ACE  activity  is  selectively  upregulated  in 
patients with ACS but serum-ACE activity is not. These observations suggest 
that  tissue-ACE  activity  may  represent  an  important  regulator  of  Ang  II 
formation at the atherosclerotic lesion. 
OTHER  DISEASES  ASSOCIATED  WITH  ACE  GENE 
POLYMORPHISMS 
ACE Polymorphism and Venous Thrombosis
The DD genotype was found as a potent risk factor for thrombosis in 
patients  undergoing  total  hip  arthroplasty.108  In  a  case-controlled study, 
Philipp  et  al  investigated  the  association  of  ACE  polymorphism, with 
postoperative  venous  thrombosis. The  plasma  ACE  levels  in  this  study 
showed  the  same  pattern  previously  reported  by  others,  with the  highest 
values  in  DD  patients,  intermediate  values  in  ID  heterozygotes, and  the 
lowest  values  in  II  patients.108 Another  study that showed  an  association 
between the DD genotype and an increased risk of venous thrombosis was 
reported  by  Dilley  et  al109 for an  African-American  population,  with  a 
threefold relative risk in men but not in women.
ACE Polymorphism and Nephropathy
Because of its central role in RAS, the ACE polymorphism has been 
extensively investigated, again with conflicting results  in renal disease,  as 
recently reviewed by Schmidt and Ritz.110 There is increasing evidence that 
the progression of diabetic nephropathy is more rapid in patients with DD 
genotype.112, 110, 111The  ACE  genotype  appears  to  predict  the  therapeutic 
efficacy of ACE inhibition of proteinuria; DD genotype patients are resistant 
to this renoprotective therapy, whereas ID and II genotype patients have a 
significant reduction in the degree of proteinuria.113, 114, 115,116. 
ACE Polymorphism and Coronary Restenosis after Stent Implantation
Because  RAS  has  been  implicated  in  the  development  of  neointimal 
hyperplasia,117 ACE activity is a crucial step for the RAS pathway, and the 
resulting increased generation of Ang II is a potent growth factor for smooth 
muscle  cells,118the  hypothesis  has  been  advanced that  genetic  factors 
affecting RAS and particularly ACE gene expression may be important in 
pathogenesis  of  coronary  restenosis after  stenting.  Indirect  experimental 
evidence  was  obtained  by demonstrating  that  ACE  inhibitors  block 
neointimal thickening after arterial balloon denudation in rats, guinea pigs, 
and  rabbits.119,  120The  clinical  relation  between  restenosis  after  coronary 
stenting and ACE polymorphism was investigated by Amant et  al121 ;  the 
association  of  the  number  of  D  alleles  and poststent  restenosis  was 
independent of other risk factors.121 The increased ACE activity due to the 
presence of the D allele, mainly in the homozygous state, may account for 
the  higher  degree of  coronary  neointimal  thickening  found  in  these 
patients.121 
ACE Polymorphism and Hypertension
The  association  between  ACE  polymorphism  and  essential 
hypertension is controversial.  A significant association of the ACE gene D 
allele with essential hypertension was documented in the African-American 
(Duru  et  al.,  1994),Chinese  (Chiang  et  al.,  1996),  and  Japanese 
populations(Morise et al., 1994; Nakano et al., 1998). On the other hand,the 
I allele was associated with high blood pressure in an Australian population 
with strong evidence of familial hypertension (Zee et al., 1992). It has been 
suggested that the population heterogeneity in the association of ACE I/D 
polymorphism  with  essential  hypertension  may  be  due  to  significant 
variations of population backgrounds (Barley et al.,1994). Response to ACE 
inhibitors in hypertensive patients appears to be determined  at least in part 
by the ACE genotype in the study of Ohmichi et al,126. 
ACE polymorphism and breast cancer;
Evidence  from  animal  models  has  suggested  that  angiotensin  II 
stimulates  neovascularisation  by  promoting  arteriolar smooth  muscle  cell 
proliferation, and this has led to increased interest in the role that angiotensin 
II  may  play  a  role in  promoting  angiogenesis  in  neoplastic  growth.  In 
addition, angiotensin II may act as a mitotic factor by inducing or regulating 
gene  expression  in  cell  cycle  progression,  and  angiotensin II  receptor 
blockade effectively reduced transforming growth factor ß1-dependent tumor 
progression in vivo . Captopril, a prototype ACE inhibitor, has been shown to 
inhibit proliferation in a variety of cell types, including human breast  cancer 
cells  126,127,128,129, and  to  reduce  tumour  growth  in experimental  models  of 
cancer 130,131 
Ace  polymorphism  was  also  studied  in  other  diseases  like 
cardiomyopathy, stroke, Alzheimer’s disease, Systemic Sclerosis.
AIM OF THE STUDY
Coronary  Artery  Disease  causes  more  deaths  and 
disability  and  incurs  greater  economic  costs  than  any  other 
illness in the developed and developing world.  A high-fat  and 
energy-rich  diet,  smoking,  and  a  sedentary  lifestyle  are 
associated  with  the  emergence  of  CAD.  These  classical  risk 
factors account for only 50% of the causes of heart disease. It is 
unknown in  50% of  the  cases.  Inherited  lipoprotein  disorders 
account  for  remainder of  the causes.  Genetic  factors play an 
important  role  in  susceptibility  to  these  disorders.  The 
knowledge of  genetic  factors  of  coronary  artery  disease may 
help in  explaining the molecular  basis  of  this  disorder  and in 
designing  prevention  and  treatment  methods.  Literature 
evidences point to the role of ACE gene I /D polymorphism in 
the  causation  of  atherosclerosis.Eventhough  ACE  gene 
polymorphism is located in intron 16 of ACE gene, it is thought 
to be in linkage disequilibrium with another functional mutation in 
the gene. The differences in the degree of linkage disequilibrium 
between this quantitative trait locus and I/D polymorphism are 
cited as a reason for the differences in the associations of the 
polymorphisms with CAD in different populations. 
The aim of the study is
1. To compare the ACE gene I/D polymorphism between cases and 
controls.
2. To compare the lipid profile values between cases and controls 
MATERIALS AND METHODS
STUDY POPULATION
CASES
The  study sample  comprised  61  unrelated  South  Indian  Coronary 
Artery  Disease  patients  (56  male,  5  female)  of  mean  age  55.1years  . 
Inclusion criteria was more than 50 % stenosis of at least one of the major 
coronary arteries. Patients with less obstruction were excluded .All patients 
with  acute  myocardial  infarction  or  unstable  angina,  and  patients  with 
ischemic or idiopathic cardiomyopathy were also excluded.
CONTROL SUBJECTS
Totally 62 controls subjects (55 male, 7 female) of mean age 55.5 
years  were  studied  and  the  controls  were  recruited  from  outpatient 
department  during  their  visit  for  non  cardiac  cases.  Age,  sex  and  other 
confounding  factors  like  diabetes,  hypertension  were  matched.  For  all 
diabetic controls, tread mill test was done .Only those with negative tread 
mill test were included in the study.
METHODS
Recumbent blood pressure and 12 lead ECG were recorded on each 
subject  after  a  thirty  minute  rest  on  the  couch.  Height  and  weight  were 
recorded and 3 mL of blood was collected by venipuncture after fortnight 
fasting in EDTA test tube. EDTA tube was centrifuged at 2000 rpm for twenty 
minutes to get the buffy coat for DNA extraction and the plasma was utilised 
for lipid profile estimation.
BUFFY COAT SEPARATION
Buffy coat was separated by centrifugation of EDTA tubes at 2000 
revolutions per minute for 20 minutes. Buffy coat was transferred to 2mL 
eppendorf and was used for DNA extraction. Plasma separated was used for 
lipid profile estimation.
BIOCHEMICAL MARKERS
Total  cholesterol  (TC),  high  density  lipoprotein  cholesterol  (HDL-c) 
and triglyceride concentration (TGL) were determined enzymatically using 
kits  and XL-300 auto  analyzer  at  Centralized Biochemistry  Laboratory at 
G.G.H,  Chennai-3.  Low  density  lipoprotein  cholesterol  (LDL-c)  was 
calculated using Friedwald’s formula.
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RBC Lysis:
• 400µL of buffy coat in a 2mL eppendorf is mixed with 1.6mL of 0.17M 
ammonium chloride and mixed by inversion until red cells are lysed 
for about 10 minutes
• The cells are centrifuged at 4000rpm for 10minutes.
• The white cell pellet is washed with 800µL of 0.17M ammonium chloride 
solution.  The procedure  is  repeated  till  a  clear  white  cell  pellet  is 
obtained.
WBC Lysis
• To the  pellet  500  µL of  TKM I  solution  is  added.  It  is  centrifuged  at 
10,000rpm for 10minutes.
Nuclear Lysis
• Discard the supernatant. To the pellet add 500 µL of TKM II solution. To 
that add 300 µL of 6M Nacl and 50 µL of 10% SDS.
• Mix well (vortex), Centrifuge at 10,000 rpm for 10 minutes.
• Save the supernatant. Transfer it to 1.5mL eppendorf.
DNA Precipitation
• To the supernatant double the volume of 100% ethanol is added.
• The sample is stored at -20◦C for 1 hour.
• Then it is centrifuged at 10,000 rpm for 20minutes at 4◦C in a refrigerated 
centrifuge.
• The supernatant is discarded. To this 500 µL of 70% ethanol is added. 
The pellet is mixed and centrifuged at 10,000 rpm for 10minutes at 
4◦C.
• Supernatant is discarded and the pellet is air dried.
Storage
• To the pellet  30 µL of  LTE buffer  is  added and the extracted DNA is 
stored at -20◦C for future use. 
Identification
• Extracted DNA was identified by 0.8% agarose gel electrophoresis with a 
constant voltage of 7V/ cm and comparison with a known molecular 
weight 1kb DNA ladder.Figure:1
POLYMERASE CHAIN REACTION
• ACE gene was amplified using,
• Forward primer – 5’-CTGGAGACCACTCCCATCCTTTCT–3’ and 
• Reverse primer – 5’-GATGTGGCCATCAATTCGTCAGAT – 3’
Primer Reconstitution 
Primers are supplied in lyophilized form. Autoclaved distilled water is 
used to prepare 100 × concentrations i.e. 10times the molecular weight of 
primer  is  the  volume of  water  required  to  prepare  100  ×  concentrations 
which is 100µmolar solution.
• From this stock solution 10 × concentration is prepared as the working 
solution for PCR.
MASTER MIX:
• Genei Red Dye master mix in the following composition was used.
• Master  Mix consists  of  a  unique inert  red dye in addition to  basic 
components necessary for PCR.
• Reaction buffer consisted of Tris Hcl -10mM at pH 8.3 KCl - 50mM
• MgCl2 - 1.5mM acts as catalyst.
• dNTP’s were used in a concentration of 2.5mM each.
• Taq polymerase in a concentration of 1.5 U.
• Primers were used in a concentration of 5 pmol and DNA was used in a 
concentration of 200ng.
• PCR was carried out in a reaction volume of 25 µL with the following 
components;
• PCR master mix– 12.5 µL
• Forward primer – 0.9 µL
• Reverse primer – 0.9 µL
• DNA – 2 .0µL
• Distilled water – 8.7 µL
• Total – 25 µL
• Amplification was carried out  in  an Mc Genei  thermal  cycler  with  the 
following cycling conditions.
• Initial denaturation – 940 C -5min
• 30 cycles of 
• Denaturation – 940C – 1 min
• Annealing - 580C – 1min
• Extension - 720C – 1min
• Final extension at 720C - 10 min.
•  Amplified products 490 bp PCR for I allele and 190bp PCR product for D 
allele was identified by agarose gel  electrophoresis by comparison 
with a known 100bp DNA ladder.  Thus, each DNA sample revealed 
one of three possible patterns after electrophoresis: a 490 bp band (II 
genotype), a 190 bp band (DD genotype), or both 490 and 190 bp 
bands (I/D genotype) Figure 2.
AGAROSE GEL ELECTROPHORESIS
• PCR product is run on agarose gel in a 50 mL agarose cast as follows: 
1g of agarose is weighed and dissolved in 50mL of TAE buffer with a 
pH of 8.0.
• It  is  microwaved for  60 secs,  cooled and 2.5 µL of  ethidium bromide 
(10mg/mL) is added. It is poured into a cast and allowed to solidify for 
15 min  before  it  is  kept  in  the  electrophoresis  tank.  8  µL of  PCR 
product is loaded onto wells and 4 µL of 100bp DNA ladder is loaded 
onto single well as a marker. It is electrophoresed at 8V/cm for 45min 
and visualized under UV illumination.
LIPID PROFILE
The  biochemical  parameters  undertaken  for  the  study  were 
determined using the following methodologies:
Estimation of Plasma Total Cholesterol
Method
Cholesterol Esterase – Cholesterol Oxidase
Kit used
Autospan of Span Diagnostics Ltd.
Principle
      Cholesterol Esterase 
Cholesterol Ester + H2O Cholesterol+ Fatty acids
   Cholesterol Oxidase
Cholesterol + O2 Cholestenone + H2O2
                    Peroxidase
H2O2 + Phenol + 4- Aminoantipyrine Red quinine + 4H2O
The concentration of cholesterol in the sample is directly proportional 
to  the  intensity  of  the  red  complex  (red  quinone),  which  is  measured at 
500nm.
REAGENTS 
Reagent 1 (Enzymes / Chromogen)
Cholesterol Esterase ≥  200U/L
Cholesterol Oxidase ≥  250U/L
Peroxidase ≥  1000 U/L
4- Aminoantipyrine 0.5 mmol/L
Reagent 1A (Buffer)
Pipes buffer, pH 6.90 50mmol/L
Phenol 25mmol/L
Sodium Cholate 0.5 mmol/L
Standard (Cholesterol 200mg/dL) 
Cholesterol 2g/L
Procedure
To 1 mL of the reconstituted reagent, 10 µL of plasma is added and 
reading is taken after 5 mins of incubation at 37o C.
Reference Values
Cholesterol : 150-260 mg /dL
ESTIMATION OF PLASMA TRIGLYCERIDE
Method
Enzymatic Colorimetric method
Kit Used
Autopak of Bayer Diagnostics
Principle
Lipoprotein Lipase
Triglyceride + H2O  Glycerol + Fatty acid
 Glycerol Kinase
Glycerol + ATP Glycerol -3- Phosphate + ADP 
     Glycerol -3- Phosphate Oxidase
Glycerol -3- Phosphate                  Dihydroxy acetone  
 phosphate + H2O2
 Peroxidase
2 H2O2 + 4 Aminoantipyrine + ADPS Red Quinone + H2O
The intensity of purple colored complex formed during the reaction is 
directly proportional to the triglyceride concentration in the sample and is 
measured at 546nm. 
REAGENTS
Reagent 1 (Enzymes / Chromogen )
Lipoprotein Lipase ≥  1100U/L
Glycerol Kinase  ≥  800U/L
Glycerol -3- Phosphate Oxidase ≥  5000 U/L
Peroxidase ≥  350 U/L
4- Aminoantipyrine 0.7 mmol/L
ATP 0.3 mmol/L
Reagent 1A (Buffer)
Pipes buffer. pH 7.50 50mmol/L
ADPS 1mmol/L
Magnesium salt 15 mmol/L
Standard (Triglycerides 200mg / dL)
 Glycerol (Trig. Equivalent) 2g/L
Procedure
To 1 mL of the reconstituted reagent 10 µL of plasma is added and 
read at 546nm after incubation at 37oC for 5mins.
Reference Range
Males 60- 165 mg/dL
Females 40- 140 mg/dL
Estimation of HDL Cholesterol
Method Immunoinhibition
Kit used - Erba XL System Packs
Principle
 Chylomicrons, VLDL, and LDL fractions in plasma are separated from 
HDL by  immunoinhibition.  Anti  human  β-lipoprotein  antibody in  reagent  
1 binds to lipoproteins (Chylomicrons, VLDL, and LDL) other than HDL. The 
antigen-antibody complexes formed block enzyme reactions when reagent 2 
is added. Cholesterol esterase and cholesterol oxidase in reagent 2 react 
only with HDL-C. Hydrogen peroxide produced by enzyme reactions with 
HDL-C, yields a blue coloured complex upon oxidase condensation with F-
DAOS and 4-aminoantipyrine (4-AA) in the presence of peroxidase(POD) . 
The intensity of the blue color complex formed at 593 nm is proportional to 
the HDL-C in the sample.
  Anti-Lipoprotein B antibody
LDL, VLDL & Chylomicrons         antigen  antibody 
complex 
        CHE & CO
HDL-C + H2O +O2  4-cholestenone + Fatty acid + H2O2
 Peroxidase
H2O2 + DAOS + 4AAP Blue colored complex + 2H2O
REAGENTS 
Reagent 1
Goods buffer pH 7.0 30.0mmol/L
4-AAP 0.9mmol/L
POD 2400U/L
Ascorbate oxidase 2700U/L
Antihuman β  lipoprotein antibody
Reagent 2
Goods buffer, pH – 7.0 30.0mmol/L
CHE 4000U/L
CO  20000U/L
F-DAOS 0.8mmol/L
Calibrator
HDL-C 56.5mg/dL
Procedure
Reagent 1 & 2 are mixed in the ratio of 3:1 or 1 bottle of reagent 1 is 
mixed with 1 bottle of reagent 2 and placed in the auto analyser with the 
following assay parameters:
Assay type : 2 point
Primary wavelength nm : 600, Secondary wavelength nm : 700
R-1 volume : 270, R-2 volume : 90
Reaction direction : increasing, Sample volume : 3 µL
Calibration : straight
Reference Values 
Adult male : 35.3 – 79.5 mg /dL
Adult female : 42.0 – 88.0 mg / dL
VLDL and LDL Cholesterol
These parameters were calculated using Friedwald’s formula given below:
LDL-C = TC - (HDL-C+ VLDL-C)
VLDL-C = TGL/5
STATISTICAL ANALYSIS
1. Allele frequencies were calculated by allele counting.
2. Age, BMI, serum lipid levels were compared between control subjects 
and patients by students t test.
3. Genotype  frequency distribution  between  cases  and  controls  were 
compared with a χ2 test for 2*2 contingency table.
4. Logistic regression analysis was performed to evaluate the interaction 
between ACE genotypes II/DD/ID and other variables in relation to the 
prevalence  of  Coronary  Artery  Disease.  Independent  variables 
included in the analysis were age (quantitative), sex (male/female), 
smoking(yes/no),  Alcoholism(Yes/No),  Hypertension  (Yes/No), 
Diabetes  (Yes/No),  Serum  Levels  of  Cholesterol,  Triglycerides 
(Quantitative). The analysis was executed by SAS Statistical program 
Version 6.10 for Macintosh.
RESULTS
Table 1 shows Age, Sex, BMI, High Density Lipoprotein levels and 
conventional  risk  factor  distribution  among patients  and  control  subjects. 
Since all the confounding factors were matched, there were no significant 
differences between the two groups. There was a significant difference in the 
High Density Lipoprotein level – low in cases (37.2+8), high in controls (51.5 
+12.5) .LDL is high in cases than controls but not significant, this could be 
because they were on treatment with cholesterol lowering medications.
Table 2.1 and 2.2 shows Genotype distribution and Allele frequencies 
of  human  ACE  gene  in  patients  with  CAD  and  control  subjects.  ACE 
genotype  distribution  was  in  agreement  with  the  Hardy-Weinberg 
expectations.
o DD genotype was more frequent among cases (65.7 %) when 
compared to controls (39.3%). In contrast ID and II was more 
common  among  controls  (61.7%)  when  compared  to 
cases(34.3%).  There  was  a  significant  difference  in  the 
distribution of II genotype also between cases and controls .P 
value is 0.001. 
o There  is  also  significant  difference  between  the  cases  and 
controls in the distribution of D and I alleles
Table 3 shows the Genotype distribution of ACE gene between I+ and 
I-  genotypes.  I+  genotype is  common among controls  (61.7%) compared 
with cases (34.3%)
Table 4 shows the age- and sex-adjusted odds ratio between I+ allele 
(ID+II  genotypes)  and  I-(DD  genotype),  was  3.  (95%  CI,  1.4  to  6.7; 
P=.01).This  shows  that  I  allele  protects  against  atherosclerosis  and 
homozygous DD genotype favors atherosclerosis.
Table 5 shows the multiple logistic regression analysis and shows that 
no  significant  difference  between  cases  and  controls  when  age,sex, 
diabetes, hypertension smoking and alcoholism are compared showing that 
all  the  confounding  variables  are  perfectly  matched  between  cases  and 
controls and there is significant difference in HDL levels (p value .000) and 
ace  genotype(p  value  0.045)  between  cases  and  controls  proving  our 
hypothesis.
DISCUSSION
 Besides very well known risk factors, genetic factors also play a role 
in  the  development  of  coronary  artery  disease.  Genetic  factors  differ  in 
various  populations.  Among  these,  ACE  gene  polymorphism  has  most 
frequently  been  studied  and  proposed  as  a  coronary artery disease risk 
factor.  ACE  gene  Polymorphism  determines  the  serum  and  tissue  ACE 
activity which is high in subjects with DD genotype (Malik et al.,  1997)134. 
ACE by causing high angiotensin II (Ang II) and low bradykinin levels may 
increase the risk of CAD (Cambien et al., 1992)135. Angiotensin II increases 
the  macrophage derived growth  factor  and platelet  derived growth  factor 
which have a role in the genesis of atherosclerosis (Keidal et al., 1993)136. 
Furthermore,  Ang II  leads to  LDL- C oxidation and stimulates neutrophil, 
macrophage and T-lymphocytes (Farber et al., 1990137; Keidal et al., 1993). 
ACE decreases nitric oxide release via the bradykinin-kallikrein system and 
causes  endothelial  dysfunction  which  has  also  an  important  role  in  the 
genesis  of  atherosclerosis.  Homozygous  deletion  subset  of  the  ACE I/D 
polymorphism is associated with deteriorated endothelial function (Mulder et 
al., 2003)138. It has been demonstrated by various studies that the ACE D 
allele is associated with the risk of CAD in various populations. However, 
other studies show that ACE gene polymorphism is not associated with CAD 
and MI.  A large case–control  study by Gardemann et al139.  on Caucasian 
samples has shown that the D allele was associated with CAD in patients 
<61.7  years  of  age,  while  Wesolowska  et  al.  studied  French  Canadian 
subjects,  and  found  that  ACE  polymorphism  is  not  associated  with 
premature CAD. 
Hence,  the  clinical  relevance  of  ACE  gene  polymorphism  still 
remains unclear. As CAD is a multifactorial disease, the ACE gene alone 
may not have a direct effect on the severity of CAD and premature death. 
However,  the  homozygous  DD  genotype  is  found  to  be  significantly 
increased in our study samples. 
In  this  study  we  have  not  confirmed  the  DD  genotypes  using 
insertion specific primers as previous studies showed that there is possibility 
of mistyping89 due to preferential amplification of D allele and all the DD 
genotype positive cases to be confirmed by using another insertion specific 
primer.  This  is  the  drawback  of  our  study.  And  we  have  not  tested  the 
phenotypic variation associated with ACE genotypes, one more limitation of 
our  study.  The present  study is  important  as  there is  a  need for a  robust 
confirmation of the risk genes for CAD, even if the effect is small, so as to 
contribute to  our  understanding of the pathology of CAD, and determine 
potential therapeutic strategies. 
CONCLUSION
Cardiovascular disease is the major cause of morbidity and mortality. 
It is well known that the etiology of this devastating disorder involves both 
genetic and environmental factors. Sequence variants of the components of 
the rennin angiotensin-aldosterone system and the kallikrein-kinin  system 
are suggested to have significant influences on cardiovascular homeostasis. 
Thus,  the  ACE gene  has  been  recognized  as  a  top  candidate  gene  for 
cardiovascular  research.  ACE  gene  polymorphism  is  involved  in  the 
pathogenesis  of  coronary artery disease via  the  plasma and tissue ACE 
levels. CAD is a preventable disease and elimination is postulated before the 
end of the 21st century .Elucidation of genetic modifiers is a prerequisite to 
genetic  screening  and  comprehensive  prevention  of  Coronary  Artery 
Disease and this is the basis of our present study. 
 In our study homozygous ACE DD genotype was more frequent in 
CAD patients compared to ID/II. The presence of even single I allele protects 
against  atherosclerosis.  Conclusively  ACE  DD  genotype  is  significantly 
associated  with  coronary  atherosclerosis.  This  association  needs  to  be 
confirmed in a large group of population.
SCOPE FOR FURTHER STUDY
1. ACE  gene  polymorphism  along  with  circulating  and  tissue  ACE 
activity, angiotensin II levels, can be done in the future to know the 
pathogenesis behind the disease.
2. ACE gene therapy can be tried in those with DD genotype. CAD,being 
a multifactorial disease this does not look promising. 
3. Pharmacogenetic studies on ACE gene I/D polymorphism will help in 
understanding individual responses to treatment and in personalizing 
treatment  regarding  type  and  dose  of  antihypertensive  medicine. 
Those with DD genotype can be given angiotensin receptor blockers 
instead of ACE inhibitors.
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